Source: Annual Congress 2002 - Community- and hospital-acquired pneumonias: inflammatory mechanisms, epidemiology and therapy
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. A. Desai, S. Sinha, P. P. Rao, R. S. Muralidharan, R. Ganesan (Mumbai, Chennai, India). Efficacy and safety of Linezolid in pneumonias. Eur Respir J 2002; 20: Suppl. 38, 2678

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of levofloxacin treatment of community-acquired pneumonia in hospitalized patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia Source: Eur Respir J 2003; 21: 135-143 Year: 2003 Linezolid: safety and efficacy monitoring Source: Eur Respir J 2012; 39: 1276-1277 Year: 2012 Linezolid: safety and efficacy monitoring Source: Eur Respir J 2012; 39: 1275-1276 Year: 2012 Safety and efficacy of CURB65 guided antibiotic therapy in community-acquired pneumonia Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Efficacy and safety of azithromycin vs. clarithromycin for the treatment of community-acquired pneumonia due to legionella pneumophila Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence Year: 2004 Efficacy and tolerability of voriconazole in the treatment of pulmonary aspergillosis Source: Eur Respir J 2007; 30: Suppl. 51, 301s Year: 2007 Efficacy and safety of stepwise therapy in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 377s Year: 2006 Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601612; DOI: 10.1183/13993003.01612-2016 Year: 2017 Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB Source: Eur Respir J 2013; 41: 1386-1392 Year: 2013 Efficacy and tolerability of linezolid in multidrug-resistant tuberculosis (MDR/XDR-TB) Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 On linezolid efficacy and tolerability Source: Eur Respir J 2012; 39: 770-772 Year: 2012 Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases Year: 2021 Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China Source: Eur Respir J 2016; 47:1591-1592 Year: 2016 Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China Source: Eur Respir J 2015; 45: 161-170 Year: 2015 Clinical efficacy and safety of micafungin in patients with pulmonary aspergillosis Source: Eur Respir J 2006; 28: Suppl. 50, 788s Year: 2006 Pulmonary aspergillosis during pregnancy: tolerability and safety of terbinafine Source: Eur Respir J 2002; 20: Suppl. 38, 352s Year: 2002 Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia Source: Eur Respir J 2004; 24 : 644-648 Year: 2004 Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis Source: Eur Respir J 2011; 38: 730-733 Year: 2011